Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Avadel Pharmaceuticals (AVDL – Research Report) today. The ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research ...

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven ...

Short AVDL slightly under 13.86, target n/a, stop loss @ 13.9 Check the time stamp on this data. Updated AI-Generated Signals ...

The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...

Warning! GuruFocus has detected 5 Warning Signs with AVDL. Release Date: August 08, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Cetera Investment Advisers trimmed its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 5.4% during the second quarter, according to the company in its most recent 13F filing with ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.